Cost-effectiveness of the screening and treatment of diabetic retinopathy. What are the costs of underutilization?
Diabetic retinal disease remains a leading cause of visual disability among those of working age. Controlled trials have demonstrated that timely diagnosis and photocoagulation treatment can reduce significantly the likelihood of visual impairment in affected diabetic patients. Using a prospective simulation model, we show that an annual screening and treatment program saves thousands of years of vision and reduces medical expenditures over the lifetime of a cohort of Swedish Type I diabetic patients.
Fendrick
A M
AM
University of Pennsylvania.
Javitt
J C
JC
Chiang
Y P
YP
D015331:Cohort Studies; D003198:Computer Simulation; D003362:Cost-Benefit Analysis; D003930:Diabetic Retinopathy / Q000453:epidemiology / Q000517:prevention & control* / Q000628:therapy*; D006801:Humans; D008962:Models, Theoretical; D013548:Sweden / Q000453:epidemiology; D013673:Technology Assessment, Biomedical; D015351:Vision Screening / Q000191:economics* / Q000706:statistics & numerical data*